Outcomes of spontaneous portosystemic shunt embolization for hepatic encephalopathy in cirrhosis—the OPAL study
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND AND OBJECTIVE: Embolization of large spontaneous portosystemic shunts (SPSSs) has emerged as a treatment for hepatic encephalopathy (HE). This retrospective multicenter Australian study investigated outcomes of SPSS embolization for persistent HE. DESIGN: Patients with cirrhosis and overt HE (grade II or more) from January 2000 to April 2025 were studied for recurrence of HE 3- and 12-month post-embolization using competing-risks analysis, along with change in maximum HE grade, ascites, variceal bleeding, and hospitalisations 1 year before and after embolization. A case-control study considering cumulative incidence of HE, liver-related death (LRD) or liver transplant (LT) was compared to those with HE and large SPSSs with no embolization from the Baveno-VI-SPSS database. RESULTS: Of 95 patients that underwent SPSS embolization with a median baseline MELD of 13 (IQR 11-16), 86 and 72% remained free of HE at 3 and 6 months. One year prior to embolization, 57 (60%) patients had West-Haven grade 3-4 HE, and 84% (48 patients) improved to HE grade ≤ 2 following embolization (p < 0.001). Higher MELD was not associated with worse outcome, and there was no difference in variceal bleeding or ascites post-embolization. Major procedural events occurred in seven patients (7%), with one LT and one death. Compared to matched historical controls without embolization (n = 149), there was a reduction in LRD/LT in the embolization group (sHR 0.59, 95% CI 0.40-0.88, p = 0.010), persisting on inverse probability of treatment weighting. CONCLUSION: SPSS embolization reduced severity and frequency of persistent HE in cirrhosis, and was not associated with increased ascites or variceal bleeding. The association of embolization with reduced LRD/LT requires further study.
Source: Hepatology International
Authors: Angus W. Jeffrey, Ken Liu, Leon A. Adams, Numan Kutaiba, Marie Sinclair, Adam Testro, Mark Goodwin, Richard Pow, Simone I. Strasser, Jarrah Spencer, James O’Beirne, Rohit Sawhney, Tamar Schildkraut, Sally Bell, Natalie Ngu, Lucy Corlette, Anna Di Bartolomeo, Michael Wallace, Martin A. Ebert, Stuart K. Roberts, Will Kemp, Thomas Reiberger, Wim Laleman, Javier Martínez, Emmanuel A. Tsochatzis, Puneeta Tandon, Virginia Hernandez-Gea, Macarena Simón-Talero, Joan Genescà, Avik Majumdar
Institutions: The University of Western Australia, Austin Hospital, Sir Charles Gairdner Hospital, Austin Health, The University of Sydney, Royal Prince Alfred Hospital, The University of Melbourne, Westmead Hospital, Griffith University, Sunshine Coast University Hospital, Eastern Health, Monash University, Monash Health, Westmead Institute for Medical Research, Macquarie University, The Alfred Hospital, Alfred Health, Medical University of Vienna, Universitair Ziekenhuis Leuven, University Hospital Münster, KU Leuven, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Universitario Ramón y Cajal, The Royal Free Hospital, University College London, University of Alberta, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Sistema Nacional de Salud, Universitat de Barcelona, Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,090
Funder: University of Western Australia
OpenAlex ID: W7236789525
